2018-A year of Pause or Persistence!

CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint,best sebi registered investment adviser, best  intraday tips providers, stock trading tips for tomorrow, sure shot  jackpot calls, stocks to buy today,financial advisory company in india,  stock market tips for intraday free, shares to buy today in indian  market, free stock tips on whatsapp, Indian stock market whatsapp group
The last year 2017 was really successful and profitable for the Indian Stock Market. This time we can say neither any cricketer nor any movie broke so many records than that our Indian Stock market did. More than 100 stocks listed in stock exchanges proved to be a million dollar stock with stupendous returns. Only Kohli and Baahubali were the record breaks but in terms of stocks we cannot count them of fingers. We can put just examples here like HEG Limited, The price of this stock on 2nd January 2017 was 147 and on 29th December 2017 the price went to 2336 closed on all-time peak, the return was 1489% isn’t it believable. There are so many Maha Baahubali stocks outperformed in 2017. 

NSE’s Benchmark Index Nifty 50 closed as a Marubozu on 2017 yearly candle, technically reflects highly bullish market.The impressive equity market returns and low levels of volatility in 2017 certainly took many by surprise, with global economic data beating expectations by the widest margin since 2010. Now Is 2018 more surprising than 2017 or it will take a pause in a bull run? What history says is after every yearly marubozu Nifty has taken pause or rise in a shallow range. It means in 2018 market again accumulates and take a breath!. Certainly the answer is not sure? 

The Wall Street bank Goldman Sachs recently forecast about U.S. Stock market for 2018 and it says the market remains bullish and S&P 500 expected to rise 11% in 2018.The much awaited U.S. tax bill is likely to pass in the early 2018. The success (or failure) of the tax bill will have a significant impact on corporate earnings growth in 2018. If the statutory corporate tax rate is cut from 35% to 21%, the calculations suggest that S&P 500 earnings could grow by 13% next year. But its history also forecasts 2018 as a year with small gains with correction. 

The interesting scenario in Indian market is that number of new traders and investors rising extensively in the last couple of months and in 2018 this figure will surely break records. Government reforms may also take pace as 2018 is the last Year for ruling party BJP to perform as Lok Sabha Elections will be held in the 1st half of 2019. The history may reflects a pause or small gain in 2018 but we cannot deny unexpected returns.

CapitalHeight Performance Weekly 12th Jan - 18th Jan 2018

CapitalHeight Cash Premium 12th-18th January 2018
CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint,best sebi registered investment adviser, best  intraday tips providers, stock trading tips for tomorrow, sure shot  jackpot calls, stocks to buy today,financial advisory company in india,  stock market tips for intraday free, shares to buy today in indian  market, free stock tips on whatsapp, Indian stock market whatsapp group
CapitalHeight Future Premium 12th-18th January 2018
CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint,best sebi registered investment adviser, best  intraday tips providers, stock trading tips for tomorrow, sure shot  jackpot calls, stocks to buy today,financial advisory company in india,  stock market tips for intraday free, shares to buy today in indian  market, free stock tips on whatsapp, Indian stock market whatsapp group
CapitalHeight Option Premium 12th-18th January 2018
CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint,best sebi registered investment adviser, best  intraday tips providers, stock trading tips for tomorrow, sure shot  jackpot calls, stocks to buy today,financial advisory company in india,  stock market tips for intraday free, shares to buy today in indian  market, free stock tips on whatsapp, Indian stock market whatsapp group

Stock to Watch for January - Kiri Industires

CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint,best sebi registered investment advisor, best  intraday tips providers, stock trading tips for tomorrow, sure shot  jackpot calls, stocks to buy today,financial advisory company in india,  stock market tips for intraday free, shares to buy today in indian  market, free stock tips on whatsapp, Indian stock market whatsapp group
Profitable Stock for January - Kiri Industries 
Daily Chart
CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint,best sebi registered investment advisor, best  intraday tips providers, stock trading tips for tomorrow, sure shot  jackpot calls, stocks to buy today,financial advisory company in india,  stock market tips for intraday free, shares to buy today in indian  market, free stock tips on whatsapp, Indian stock market whatsapp group
Technical Analysis 
Kiri Industries formed wedge pattern on daily chart and it breaks out with high volume. If we draw a trend line from 27 November high, extended to 11 December high and 22 December high then it is an upper trend line of the wedge pattern. The stock was contracting in a narrow range in the past 15 to 20 days and recently it breaks the trend line with good volume. 
It holds perfect support at 68.3 days Fibonacci EMA support on daily chart. On a broad chart the stock is consolidating in a 4th wave of Elliot Wave pattern and a break out will extends the uptrend to 5th wave. We expects a strong up trend in the next 2 to three week and one can hold the position for a period of 1 or 2 month. Buy Kiri Industries between 520 and 550 for the targets 680-730 with stop loss below 490. Intraday Traders can buy the stock for the target of 560-570.

Profitable Stocks to Trade in December, 2017 - Dr Lal Pathlavs

Dr Lal PathlavsPvt Ltd. Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company Dr Lal PathlavsPvtLtdThe Company was incorporated as Dr. Lal PathLabs Private Limited, a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. The Company was converted into a public company pursuant to a special resolution of the shareholders of our Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to Dr. Lal PathLabs Limited and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015 
  • Over 3000 individuals work at the Dr Lal PathLabs in India with over 55 percent of the staff in laboratory functions 
  • Qualified team of 147 Pathologists, 8 Radiologists, 13 Microbiologists , 5 Biochemists and 11 specialists with doctorate degrees 
  • There is a growing pool of young leadership from top institutions like AFMC, IIMs, IITs , XLRI, SP JAIN amongst others 
  • Dr Lal PathLabshonoured with Frost and Sullivan 4th Annual India Healthcare Excellence Award, 'Diagnostic Service Provider Company of the Year 2012 
  • Dr Lal PathLabs recognized by IBM - amongst top 50 brands in India for Marketing & IT •Satellite laboratories at Punjabi Bagh& NOIDA & Clinical Trials Laboratory, Gurgaon receive NABL accreditation as per ISO 15189 (2007 
  • Six Laboratories of Dr Lal PathLabs namely Main Laboratory, Reference Laboratory, Satellite laboratories at Gurgaon, SDA, PreetVihar and Mumbai successfully upgrade the NABL Quality Standard from ISO 

FUNDAMENTAL ANALYSIS 
Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 56% by 2020.The group's activity appears highly profitable thanks to its outperforming net margins.Thanks to a sound financial situation, the firm has significant leeway for investment.Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock. Beta of the stock for one month range is 0.089. 
  • Company is virtually debt free. 
  • Promoter's stake has increased. 
  • Company has a good return on equity (ROE) track record: 3 Years ROE 30.63% 
  • Net sales have increased from 241.80 cr to 269.30 cr in last quarter 
  • PBDIT have increased from 63.50 cr to 74.90 cr last quarter 
  • Net profit has increased from 43.10 to 50.20 cr last quarter 
  • Company P/E is 47.25 which is less than industry P/E of 52.47 which indicates that company is undervalued. 

Technical Analysis 
Dr. Lalpath Lab shows very strong positive trend in the last 4 weeks. It recovered nearly 25 percent from its bottom. The stock formed hammer pattern on monthly chart and also gave confirmation as it formed strong bullish candle in November month. It formed low of 775 and high of 908 finally settled at 889 on the last working day of November. From the last 8 trading sessions the stock is in tight consolidation range and ready for break out now. 
  • If we draw a trend line from the highs of June 2011 then the stock has given break out of this long term trend line on weekly chart 
  • If we draw a trend line from the lows of January 2017, then the stock managed to sustain above it and it works as a strong support now. 
  • 900 is the strong psychological as well as monthly resistance , weekly closing above 900 will confirms the uptrend. 
  • 900 should be breached by heavy volume to generate short term momentum in the stock 

Buy Lalpath Lab above 900 for the target of 990 and 1040 with the stop loss below 815. Less Risky trader can maintain stop loss below 855 

Supports and Resistance (Monthly) 
  • Resistance 1- 955 Supports 1- 815 
  • Resistance 2- 1040 Support 2- 750 
  • Resistance 3- 1150 Support 3- 690 

Lalpath Lab WEEKLY CHART
CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint,best sebi registered investment advisor, best  intraday tips providers, stock trading tips for tomorrow, sure shot  jackpot calls, stocks to buy today,financial advisory company in india,  stock market tips for intraday free, shares to buy today in indian  market, free stock tips on whatsapp, Indian stock market whatsapp group

Profitable Stock to Watch for Trade in December - MAJESCO

CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint, bank nifty levels, bank nifty support levels, CapitalHeight Complain, Capitalheight Complaint, clossing bell, daily nifty, free nifty live, free nifty tips, free nifty view, Indian Rupee Update, nifty, nifty down, nifty index, nifty live, Nifty Market Trend, nifty market trends, nifty related news, nifty report, nifty support, nifty support levels, nifty up, nifty up or down, nifty view today, nifty50, nifty50 news
Majesco is a provider of core insurance technology software and IT services to insurance carriers worldwide. Majesco delivers software and IT services in core insurance areas including policy administration, product modeling, new business processing, billing, claims, producer lifecycle management and distribution.Majescoprvides technology solutions, products and services for the insurance industry across lines of business – Property & Casualty (General Insurance), Life, Annuity, Health, Pensions, and Group & Worksite Benefits insurance. The company focus on delivering business value and enhanced business capabilities to clients through a combination of world-class enterprise grade products in modern technologies, implementation services and specialized application services. 
  • The Majesco Named a ‘Visionary’ in Gartner’s Magic Quadrant for P&C Insurance Claims Management Module 
  • Majesco Positioned as a Leader in Gartner’s First Magic Quadrant for P&C Insurance Policy Management Modules 
  • Majesco Customer, AssureStart, Receives SMA Innovation in Action Award 

Fundamental Analysis 
The company has market cap of around 1308 crore and On the positive side, the company was able to report operating profit of Rs 1.7 crore after reporting operating loss of Rs 1 crore in the previous quarter. In addition, its net profit was Rs 1.5 crore compared with the loss of Rs 2 crore in the March quarter. The US market contributes nearly 89 per cent to its revenues, while the UK generates 7 per cent of the revenue. The company caters to 164 clients in the property and casualty (P&C) and Life & annuity segments. P&C contributes 80 percent Of the revenue. The company expects to clock revenue of $200-225 million by FY18 compared with $113 million in FY16. It also expects to improve operating margin before depreciation (EBITDA margin) substantially to 12-14 per cent from just over half a percent in FY16. Beta of the stock for one month range is 0.032. 
  • Company is virtually debt free which is very good for the financial health of a company. 
  • Net profit of the company has increased from 1.11 crore to 9.96 crore in last quarter 
  • Net sales of the company has increased from 4.50 crore to 5.13 crore in the last quarter 
  • Company has good ratio of promoter Stack which is around 50% 
  • Return on equity ratio has increased from 5.25% to 6.88% 
  • Return on capital employed ratio increased from -2.01% to 5.96% 
  • Operating profit margin increased from 1.8% to 6.19% 

Technical Analysis 
Majesco Performed very well in the second half of 2017 when it bottomed out around 300 in July, Since then it the stock almost doubled in its value. Since last two weeks the stock recovered again from its correction mode also formed bullish engulfing pattern on weekly chart. It gained nearly 80 points in the last two weeks and again heading to break recent monthly high. 
  • The stock formed a flag like structure on weekly chart, it is not very accurate but if break out comes with heavy volume it will work. 
  • The stock recovered earlier three times with the support of 14 day EMA and it works fine on weekly chart 
  •  590 is the monthly resistance and 470 is the strong support, price may come a little down near 530 once. 
  • 540 is the historical monthly support and the stock should not give weekly closing below this level. 21 day EMA on daily chart also supports the stock 

Buy Majesco between 530 and 550 for the target of 630-650 and maintain stop loss below 470 

Supports and Resistance (Monthly) 
  • Resistance 1- 590 Supports 1- 470 
  • Resistance 2- 650 Supports 2- 425 
  • Resistance 3- 735 Supports 3- 390 

MAJESCO WEEKLY CHART
CapitalHeight, CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint, , bank nifty levels, bank nifty support levels, CapitalHeight Complain, Capitalheight Complaint, clossing bell, daily nifty, free nifty live, free nifty tips, free nifty view, Indian Rupee Update, nifty, nifty down, nifty index, nifty live, Nifty Market Trend, nifty market trends, nifty related news, nifty report, nifty support, nifty support levels, nifty up, nifty up or down, nifty view today, nifty50, nifty50 news

Profitable Stocks in Falling Market- Biocon Limited

Biocon Limited, a fully integrated healthcare company was incorporated in the year 1978 as a joint venture between BioconBiochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. The Companys business model spans the entire drug value chain, from pre-clinical discovery to clinical development and through to commercialisation and focused on biopharmaceuticals, custom research and clinical research. Biocon is an ISO 9001, ISO 14001:2004, ISO 9001:2000, ISO 15189:2003 and also OHSAS 18001:1999 certified for various levels. Biocon have two subsidiary companies for support, namely Syngene International Ltd and Clinigene International Ltd. Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and several other molecules at exciting stages in the biopharmaceutical value chain.OncologyBiocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the BioconBiochemicals Limited in Ireland and merges it with its subsidiary, Quest International 

  • The commercial success of Biocons proprietary fermentation plant leads to a 3-fold expansion during the year 1996 and also in the same year, the company had leveraged its technology platform to enter biopharmaceuticals and statins. Biocon had spearheads initiatives in human healthcare in the year 1997 through a dedicated manufacturing facility. 
  • As at January 2008, Biocon Limited and IATRICa, Inc made a strategic partnership to co-develop an exclusive new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. 
  • Abu Dhabi based pharmaceutical company Neopharma had signed an MOU with the company to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council) in the year 2007. 

Fundamental Analysis 
Biocon Limited (“Biocon” or the “Company”) was set up in the year 1978 as a joint venture between BioconBiochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon is a fully integrated biopharmaceutical company focused on biopharmaceuticals, customized research and clinical research. The Company has developed a robust drug pipeline and offers active pharmaceutical ingredients (APIs), including cardiovascular agents, anti-obesity agents, oral anti-diabetic agents, anti-inflammatory agents and digestive-aid enzymes.The Company also has commercial and marketing agreements with Pfizer and Ferozsons Laboratories Limited, and licensing agreement with AbraxisBioScience, Inc, as well as strategic collaboration for insulin products with Mylan, Inc.The Company’s brands include Herceptin, Enbrel, MabThera, Remicade, Lantus, Humalog and NovoLog. Beta of the stock for one month range is 0.028. 
  • Average 2 year ROE of Biocon Ltd. 16% 
  • Bought by 34 mutual fund schemes and sold by only 26 mutual fund schemes in last quarter. 
  • The Company has maintained an average dividend yield of 0.82 % over the last 5 financial years.  
  • Net sales of the company has increased from 574.30 crore to 604.70 crore and net profit has increased from 54.50 to 68.40 crore in last quarter 
  • Biocon’s average interest coverage ratio over the last 5 financial years has been 122.48 times which indicates that the Company has been generating enough for the shareholders after servicing its debt obligations. 

Technical Analysis 
Biocon is again on its all-time high levels after split some times before. In the end of 2016 the stock started its major uptrend and gained more than 150 percent in just around 1 year of time period backed by strong fundamentals. Despite of negative trend in the Index in the last week of November the stock managed to close at its highest levels. Earlier the stock swing between 50 points from the last 8 to 10 weeks and now going for new highs. 
  • On weekly chart the stock is trading in a broadening triangle pattern 
  • Broadly the pattern has completed 45 weeks and heading towards its upward trend line 
  • If we draw a trend line from the highs of November 2016 and July 2017, the extension will given the upper range of the stock 
  • 55 day EMA clearly supports the trend line and the stock respects its earlier also on weekly chart ADX also gave cross over on the previous week strong closing 

Buy Biocon December futures between 440 and 450 for the target of 490 to 500 and maintain stop loss below 415. 

Supports and Resistance (Monthly) 

  • Resistance 1- 480 Supports 1- 415 
  • Resistance 2- 515 Supports 2- 387
  • Resistance 3- 550 Supports 3- 355 

Biocon WEEKLY CHART
CapitalHeight Review, CapitalHeight Complain, CapitalHeight Complaint, CapitalHeight, bank nifty levels, bank nifty support levels, CapitalHeight Complain, Capitalheight Complaint, clossing bell, daily nifty, free nifty live, free nifty tips, free nifty view, Indian Rupee Update, nifty, nifty down, nifty index, nifty live, Nifty Market Trend, nifty market trends, nifty related news, nifty report, nifty support, nifty support levels, nifty up, nifty up or down, nifty view today, nifty50, nifty50 news

WEEKLY PERFORMANCE (4-8 DECEMBER 2017) – FUTURE PREMIUM

CapitalHeight is equipped with a team of the best and most experienced professionals who work with full devotion towards benefiting customers and helping them and their capital achieve new heights. Our analysis is solely based on the economic news and deep technical analysis done by our experts. 
We had provided total 20 calls in this week in Cash Premium Segment and provided 95% Accuracy. You can check our daily report on our Website.
Important Links :-
Stock to Watch for Monday -
http://moneycapitalheight.blogspot.in/p/stocks-to-watch-today.html